KYAN Therapeutics' technology platform identifies novel and effective nucleic acid therapies for MYC-driven liver cancer

Study published in Bioengineering & Translational Medicine

SINGAPORE, SINGAPORE, September 17, 2022 /EINPresswire.com/ -- MYC is a transcription factor that is dysregulated in over 70% of human cancers, making it an important target that unfortunately, has been deemed “undruggable” for many years. Although synthetic lethality has offered a promising parallel approach that targets MYC-dependent vulnerabilities in cancer, there is still no targeted synthetic lethality therapy against MYC-driven cancers that has been approved for clinical use. A major challenge to getting MYC synthetic lethality targets into clinical settings is the need to prioritize targets by therapeutic potential for each MYC-driven cancer type due to the dissimilarities of tumors in each type.

Taking into account the need for target prioritization and an increase in the exploration of combination therapies against MYC-driven cancers, the researchers in this study used KYAN’s experimental–analytical hybrid platform to find MYC synthetic lethal targets with the greatest therapeutic potential and compared their therapeutic value to current standard-of-care drugs in MYC-driven hepatocellular carcinoma (HCC). The researchers further utilized technology from KYAN and the Agency of Science, Technology & Research (A*STAR)'s Institute of Molecular and Cell Biology (IMCB) to identify a two-drug combination of novel splice-switch oligonucleotides (SSOs) as promising therapeutic candidates for MYC-driven HCC.

“We are thrilled that our collaboration with IMCB is already generating such exciting results,” said Hugo Saavedra, CEO of KYAN Therapeutics. “Being able to aid drug discovery is yet another valuable tool that helps us to build solutions for better cancer care.”

About KYAN

KYAN Therapeutics is a biotechnology company on a mission to bridge the cancer care gap by advancing revolutionary technologies. Our technology platforms were developed in collaboration with UCLA and the National University of Singapore, combining small data AI and biological experiments to define how therapies are developed and offered to patients. From drug development to personalized medicine, KYAN offers an efficient solution to identify the optimal outcome to millions of possible drug-dose combinations. KYAN's technology has been peer reviewed in several reputable and high impact factor journals and implemented in multiple

clinical studies.

For more details, please visit https://www.kyantherapeutics.com

Media Contact
Lisa Chow
email us here
Visit us on social media:
LinkedIn
